D.E. Shaw & Co’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

D.E. Shaw & Co’s Portfolio ORTX Stock Details ORTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-22,627	Closed	-$132K	–	5652
2022 Q2	$132K	Buy	+22,627	New	+$128K	﹤0.01%	4672
2020 Q3	–	Sell	-5,650	Closed	-$339K	–	4256
2020 Q2	$339K	Buy	5,650 +1,815	+47%	+$166K	﹤0.01%	3573
2020 Q1	$289K	Buy	3,835 +2,377	+163%	+$274K	﹤0.01%	3487
2019 Q4	$200K	Buy	+1,458	New	+$177K	﹤0.01%	3800
2019 Q3	–	Sell	-1,690	Closed	-$236K	–	4071
2019 Q2	$236K	Buy	+1,690	New	+$297K	﹤0.01%	3404

Other funds holding ORTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co's ORTX Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q3 2022, closing a stake of 22,627 shares — an estimated $132K sold.

D.E. Shaw & Co first reported a position in ORTX in Q2 2019 and held it in 5 quarters. The position peaked at $339K in Q2 2020. 47 funds tracked by Wall St. Rank hold ORTX as of Q3 2022.

D.E. Shaw & Co reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q3 2022 after selling out during the quarter.
D.E. Shaw & Co sold 22,627 Orchard Therapeutics plc American Depositary Shares shares in Q3 2022, an estimated $132K.
D.E. Shaw & Co first reported a position in Orchard Therapeutics plc American Depositary Shares in Q2 2019 and held it in 5 quarters.
D.E. Shaw & Co's Orchard Therapeutics plc American Depositary Shares position peaked at $339K in Q2 2020.
47 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.